Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen

Borrás-Blasco, Joaquı́n; Gracia-Pérez, Antonio; Rosique-Robles, J Dolores; Casterá, M Dolores-Elvira; Abad, F Javier

doi:10.1517/14712590903530633

Cited by 49 publications

(48 citation statements)

References 17 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, RA patients administering methotrexate with an AI experience less pain and prefer it over the PFS [21,22]. Selfinjection by AI is also preferred by patients using adalimumab [23,24], etanercept [25][26][27], and golimumab [28,29], as well as in other disease areas, such as diabetes and growth hormone deficiency [30][31][32].…”

Section: Discussionmentioning

confidence: 99%

Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis

Domańska

VanLunen

Peterson

et al. 2016

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Objectives: To compare the usability of a new certolizumab pegol (CZP) autoinjector with the adalimumab, etanercept, and golimumab devices in patients with rheumatoid arthritis. Methods: Two identical studies were performed in 2013 and 2016; patients performed a simulated selfinjection with the CZP autoinjector and the most up-to-date device versions at the time in a randomized, consecutive sequence. The primary end point was the ranking of the four autoinjectors in order of preference. Device usability and intuitiveness were assessed across a range of secondary and exploratory end points. Results: The 2013 and 2016 study populations included 76 patients each; a significant majority (2013: 67%; 2016: 59%) ranked the CZP autoinjector as their most preferred device (p < 0.001). Most patients agreed that the CZP autoinjector was easier to use, start, and manipulate, and were more willing to use it than the comparator devices (p < 0.001 for all pairwise comparisons with CZP). Likert score differences also favored the CZP autoinjector regarding how easy it was to determine injection completion. The CZP autoinjector was associated with a low rate of use error. Conclusions: In both studies, the CZP autoinjector was the preferred choice compared to the alternative devices and was associated with a high level of patient satisfaction. ARTICLE HISTORY

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis

Domańska

VanLunen

Peterson

et al. 2016

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

show abstract

“…Several commercial subcutaneous products up to 1 mL are available, including Enbrel (Amgen, Thousand Oaks, CA), Humira (AbbVie, North Chicago, IL), Simponi (Janssen Biotech, Horsham, PA), and Stelaris (Janssen Biotech). [5][6][7][8][9] When the therapeutic dose can be formulated in 1 mL, prefilled syringes and autoinjectors typically serve as the preferred delivery systems for subcutaneous selfadministration. 6,10 To limit the injection volume to 1 mL, monoclonal antibody formulations often need to be formulated at high concentrations at !100 mg/mL.…”

Section: Introductionmentioning

confidence: 99%

“…[5][6][7][8][9] When the therapeutic dose can be formulated in 1 mL, prefilled syringes and autoinjectors typically serve as the preferred delivery systems for subcutaneous selfadministration. 6,10 To limit the injection volume to 1 mL, monoclonal antibody formulations often need to be formulated at high concentrations at !100 mg/mL. High-concentration liquid monoclonal antibody formulations can present problems in manufacturing and delivery because of high viscosities, limitations of protein solubility, aggregation, and protein stability under long-term storage.…”

Section: Introductionmentioning

confidence: 99%

Understanding Subcutaneous Tissue Pressure for Engineering Injection Devices for Large-Volume Protein Delivery

Doughty¹,

Clawson²,

Lambert³

et al. 2016

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…Since then, a number of other bDMARDs have been approved and are now commercially available; many of these treatments are administered by subcutaneous (SC) injection, with a number of presentations and devices currently being available (prefilled syringes, vial and syringe, and autoinjector devices). A number of studies have reported that patients with RA prefer autoinjector devices over conventional methods of treatment administration, with patients citing such factors as these devices being easier to use, more convenient, more acceptable, less painful, and less time-consuming [5–7]. …”

Section: Introductionmentioning

confidence: 99%

Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe

et al. 2016

View full text Add to dashboard Cite

IntroductionBenepali® was the first etanercept (Enbrel®) biosimilar to be approved in the European Union. Both Benepali and Enbrel are available as autoinjector devices. In a recent survey, nurses from France, Germany, Italy, Spain, and the United Kingdom (UK) reported that their patients with rheumatoid arthritis (RA) would prefer the Benepali autoinjector compared to the Enbrel MYCLIC autoinjector. To determine whether patients’ perceptions were similar to those of the nurses, this survey evaluated patients’ perceptions and preferences of the Benepali autoinjector versus the Enbrel MYCLIC autoinjector in the same five European countries.MethodsPatients with RA using the Enbrel MYCLIC autoinjector participated in a 25-min, face-to-face questionnaire-interview. Patients were also shown an instructional video and device-handling leaflet, received a live demonstration on the Benepali autoinjector, and had access to both Benepali and Enbrel MYCLIC training autoinjectors. Patients rated the importance of ten autoinjector attributes on a seven-point scale (1 = not important at all; 7 = extremely important) and provided their autoinjector preferences based on specific attributes. Patients also gave their opinion on which autoinjector they would prefer to use for self-injection.ResultsOverall, 220 patients participated in the survey (France, n = 30; Germany, n = 65; Italy, n = 67; Spain, n = 12; UK, n = 46). ‘Easy to operate the self-injection’ was ranked as the most important attribute (mean score of 6.8), followed by ‘easy to grip’ (6.5), and ‘intuitive/self-explaining usage’ (6.3). Patients preferred the Benepali autoinjector, with the attribute of ‘easier to operate’ being a strong differentiator compared to the Enbrel MYCLIC autoinjector. Most patients (74%) reported that they would prefer to use the Benepali autoinjector over the Enbrel MYCLIC autoinjector. ‘Easy to operate the self-injection’ and ‘button-free autoinjector’ were key drivers when selecting an autoinjector.ConclusionsPatients in Europe reported a preference for the Benepali autoinjector compared to the Enbrel MYCLIC autoinjector. This finding is consistent with results from a recently reported nurse survey. Funding: Biogen.Electronic supplementary materialThe online version of this article (doi:10.1007/s40744-016-0048-9) contains supplementary material, which is available to authorized users.

show abstract

Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen

Abstract: This study provides further evidence to support the use of the autoinjection pen as a delivery option for adalimumab therapy.

Cited by 49 publications

References 17 publications

Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis

Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis

Understanding Subcutaneous Tissue Pressure for Engineering Injection Devices for Large-Volume Protein Delivery

Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe

Contact Info

Product

Resources

About